Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Shares of Eli Lilly & Co. LLY inched 0.35% higher to $729.73 Tuesday, on what proved to be an all-around mixed trading ...

Verge Genomics announced that Eli Lilly (LLY) has opted to pursue the development of therapeutics against two validated drug targets for ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Eli Lilly and Company (LLY) announced that it has elected Jon Moeller as a new member of its board of directors, effective Dec. 1. In addition, the company announced that Karen Walker will transition ...

Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...